Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
about
Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple MechanismsTargeting Cell Survival Proteins for Cancer Cell DeathCurrent challenges and novel treatment strategies in double hit lymphomasUnderstanding platelet generation from megakaryocytes: implications for in vitro-derived plateletsPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Regulation of Bim in Health and DiseaseNovel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyNew molecular targets in mantle cell lymphomaCancer stem cells--important players in tumor therapy resistanceBcl-2 antagonists: a proof of concept for CLL therapySystems biology of cisplatin resistance: past, present and futureBcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysisBAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial poreTargeting the apoptosis pathway in hematologic malignanciesSmall Molecule Inhibition of the TNF Family Cytokine CD40 Ligand through a Subunit Fracture MechanismThe restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonistStructure-Guided Rescaffolding of Selective Antagonists of BCL-X LDiscovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based designBh3 induced conformational changes in Bcl-Xl revealed by crystal structure and comparative analysisThe potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaThe biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemiaAlternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem CellsTargeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenograftsBM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivoSelectivity by small-molecule inhibitors of protein interactions can be driven by protein surface fluctuationsInhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXALarge-scale pharmacological profiling of 3D tumor models of cancer cells.The use of therapeutic peptides to target and to kill cancer cells.High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37.A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survivalMegakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets.Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human plateletsABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibitionBoth leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.The role of apoptosis in megakaryocytes and platelets.Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan.Platelet production proceeds independently of the intrinsic and extrinsic apoptosis pathways.
P2860
Q26751444-58E92CF8-6C8B-4C49-8D0E-0A07746A5524Q26765447-9A005502-2AE3-445A-95F5-52AD2F0EB8B9Q26770385-5B771142-6862-4443-9066-962214D34746Q26770860-23EDF8B9-0688-4164-99BB-21997BD6CA72Q26771601-335BB56C-ECFA-4CD5-A7B6-57FC287D104FQ26781203-6F75E56A-04F8-4C9E-B5B7-CD318C0154D1Q26782270-81774B3D-F9D9-4057-8249-D36A4158518EQ26821766-11B44833-08C4-4A1E-980C-DC6FD6B285EFQ26823015-94542A30-1DDE-4A50-AA89-727FDA7E8932Q26823996-2F8C000A-8B14-4975-BF28-0FEBE66C17DBQ26863585-B1405458-FBD4-4093-9229-820C5804C61CQ27001269-E6D5A79C-CC01-4DA0-AAE8-3E591FFE236FQ27002044-E76B9EC2-2332-4AAD-9524-65B0FB65D122Q27024422-DE586399-DEAC-4BE1-B718-677F356A6F1EQ27667288-45EEEF30-08E8-4F2C-A2C8-A40510FBD841Q27675459-1EAD869B-500D-4AC1-BE56-730AE3011443Q27684386-E20A509F-DD2F-4EE2-8D11-5C6BDF2E78B6Q27700088-030EDD11-04FF-4F62-AC47-A6F1FD0DA32DQ27700247-F968B0F5-330D-4F00-B881-E376B51C21DFQ28075504-80624373-B840-4FDC-8A68-9308B03A27D7Q28075683-A77B93B9-1EFA-4704-BB97-AE14137E1229Q28084243-50897E1E-649C-41EC-993D-19841BBFDC6FQ28538631-21D1625B-F7D4-46A8-94CE-6BD4A3ABDEBBQ28539452-D784B6DB-68F7-44CC-9D28-BB095571B385Q28543593-E23285B7-B533-4858-A6AB-2F1B5AFF5AFCQ28830560-EA31CDCC-5F3A-4791-90AD-2391E4162082Q30364972-2EFEE3FE-E948-4B8A-89BF-DFCAD05D40C9Q30418414-68CF2E49-DEF1-4A59-BFBB-FD19E8BD7C17Q30433183-5E377D0E-9DE6-4AA8-B877-24F5D09B2A36Q31055813-45829466-9C6B-472F-9FA4-6EA9FCDF522EQ31100573-48319FAD-EAF9-4013-8409-743CD4F9AAA3Q33397149-E2CEA4C7-3E4E-4DE9-A631-BCB674B204E9Q33398808-FCA32788-7B0C-4498-9E3C-F7AA89682C6DQ33403953-F091A5E8-4551-40E7-9C11-FE5A925B7119Q33405436-D396D198-7EF1-4A52-A759-4162C390BE8CQ33407258-7961307A-833A-4291-821E-91F0D644C3C8Q33412553-33CF4F5B-2A6E-477D-B9B5-4D479DB3F7B1Q33412943-8E6C8626-4DF5-419B-9D3C-098E4B22D057Q33413694-6644E988-5907-421D-B9C1-D8002225432DQ33413970-F1F25517-8900-444F-BBCE-F0649639CBAA
P2860
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Navitoclax, a targeted high-af ...... mics, and antitumour activity.
@ast
Navitoclax, a targeted high-af ...... mics, and antitumour activity.
@en
type
label
Navitoclax, a targeted high-af ...... mics, and antitumour activity.
@ast
Navitoclax, a targeted high-af ...... mics, and antitumour activity.
@en
prefLabel
Navitoclax, a targeted high-af ...... mics, and antitumour activity.
@ast
Navitoclax, a targeted high-af ...... mics, and antitumour activity.
@en
P2093
P2860
P1433
P1476
Navitoclax, a targeted high-af ...... mics, and antitumour activity.
@en
P2093
Andrew P Krivoshik
Anil Tulpule
Ann S LaCasce
John F Gerecitano
John P Leonard
Kieron Dunleavy
Myron S Czuczman
Owen A O'Connor
Rod A Humerickhouse
P2860
P304
P356
10.1016/S1470-2045(10)70261-8
P577
2010-11-18T00:00:00Z